带状疱疹神经痛患者应用普瑞巴林致肌阵挛的药学监护

doi:10.19803/j.1672-8629.2021.04.19

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (4): 381-383.
DOI: 10.19803/j.1672-8629.2021.04.19

带状疱疹神经痛患者应用普瑞巴林致肌阵挛的药学监护

蔡江霞, 杜宪, 孙培环, 张笑颖, 刘涛, 叶银梅^*

新疆巴音郭楞蒙古自治州人民医院药学部,新疆库尔勒 841000

收稿日期:2019-12-20 出版日期:2021-04-15 发布日期:2021-04-23
通讯作者: ^*叶银梅,女,主任药师,临床药学。E-mail：1335233425@qq.com
作者简介:蔡江霞,女,硕士,主管药师,临床药学。
基金资助:
国家自然科学基金资助项目（71904155）

Myoclonus Caused by Pregabalin in Patients with Herpes Zoster Neuralgia and Literature Analysis

CAI Jiangxia, DU Xian, SUN Peihuan, ZHANG Xiaoying, LIU Tao, YE Yinmei^*

Department of Pharmacy, the People's Hospital of Xinjiang Bayinguoleng Mongolian Autonomous Prefecture, Korla Xinjiang 841000, China

Received:2019-12-20 Online:2021-04-15 Published:2021-04-23

摘要/Abstract

摘要： 目的探讨普瑞巴林与二氢吡啶类钙通道拮抗剂（calcium channel blockers, CCB）类降压药联用的安全性及药学监护。方法基于1例带状疱疹神经痛患者应用普瑞巴林致肌阵挛的病例,查阅国内外文献并结合其疾病特点及用药,对患者发生肌阵挛的原因进行分析评价,总结出药品不良反应（ADR）防范及药学监护要点。结果普瑞巴林与CCB类降压药物需谨慎联用,若联用需做好相应的监护。结论临床药师参与临床治疗药物监护有利于保障患者的药物选择、用药禁忌、ADR防范等方面用药安全。

关键词: 带状疱疹神经痛, 普瑞巴林, 钙通道拮抗剂, 药品不良反应

Abstract: Objective To investigate the safety and pharmaceutical care of pregabalin used in combination with CCB antihypertensive drugs. Methods Based on one case of pregabalin-induced myoclonus in a patient with herpes zoster neuralgia, the clinical pharmacist reviewed domestic and foreign literature, studied the characteristics of the disease and medication, analyzed the causes of myoclonus in the patient, and summarized the bottom line of prevention of adverse reactions and pharmaceutical care for clinical reference. Results The clinical pharmacist proposed that the combination of pregabalin and CCB antihypertensive drugs be used with caution. Conclusion It is essential that clinical pharmacists participate in the monitoring of clinically-used drugs, which can contribute to drug safety of patients and prevention of adverse reactions.

Key words: herpes zoster neuralgia, pregabalin, calcium channel antagonist, adverse drug reaction

中图分类号:

R994.1

蔡江霞, 杜宪, 孙培环, 张笑颖, 刘涛, 叶银梅. 带状疱疹神经痛患者应用普瑞巴林致肌阵挛的药学监护[J]. 中国药物警戒, 2021, 18(4): 381-383.

CAI Jiangxia, DU Xian, SUN Peihuan, ZHANG Xiaoying, LIU Tao, YE Yinmei. Myoclonus Caused by Pregabalin in Patients with Herpes Zoster Neuralgia and Literature Analysis[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 381-383.

参考文献

[1] Ma LM, Shi DP, Li C, et al.Efficacy and safety of rabbit skin extract injection induced by vaccinia vaccine in the treatment of postherpetic neuralgia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(5): 266-269.
[2] Jin X, Zou XD, Zhang ZZ.A case report and literature review of muscle tremor caused by pregabalin[J]. Journal of Chinese New Drugs and Clinical Medicine(中国新药与临床杂志), 2017, 36(7): 434-436.
[3] Olszewska DA, Chalissery AJ, Williams J, et al.Speech myoclonus due to probable pregabalin adverse drug-reaction[J]. Parkinsonism Relat Disord, 2015, 21(7): 823-824.
[4] Bamanikar A, Dhobale S, Lokwani S.Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia[J]. Indian J Pharmacol, 2013, 45(5): 522-523.
[5] Kaufman MB, Choy M.Pregabalin and simvastatin: first report of a case of rhabdomyolysis.[J]. Pharm Ther, 2012, 37(10): 579-595.
[6] Shilpa R, Sreekrishnan TP, Kumar KPG, et al.A case report on pregabalin-induced eosinophilia[J]. Consult Pharm, 2018, 33(6): 317-320.
[7] Kui XM, Yan W, Qin QJ, et al.A case report of drowsiness, ataxia and aphasia induced by Pregabalin capsule[J]. Chinese Pharmacist(中国药师), 2018, 21(9): 1631-1632.
[8] Perez Loret S, Amaya M, Merello M.Pregabalin-induced parkinsonism: a case report[J]. Clin Neuropharmacol, 2009, 32(6): 353-354.
[9] Masmoudi I, Gras-Champel V, Barbieux-Vaquez D, et al.Pregabalin-induced parkinsonism: A case report[J]. Therapie, 2017, 72(3): 395-396.
[10] Park KD, Kim MK, Lee SJ.Negative myoclonus associated with pregabalin[J]. Yeungnam Univ J Med, 2018, 35(2): 240-243.
[11] Desai A, Kherallah Y, Szabo C, et al.Gabapentin or pregabalin induced myoclonus: A case series and literature review[J]. J Clin Neurosci, 2019, 61: 225-234.
[12] Wu ZS, Yao CH, Zhao D.Epidemiological study on the incidence and mortality of cerebral apoplexy in Chinese population[J]. Journal of Chinese Epidemiology(中华流行病学杂志), 2003, 24(3): 236-239.
[13] Naranjo CA, Busto U, Sellers EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30: 239-245.
[14] Chen BQ, Li CW, Shi YP, et al.Pharmacological action and clinical evaluation of pregabalin[J]. Journal of Chinese New Drugs and Clinical Medicine(中国新药与临床杂志), 2010(1): 11-14.
[15] Qureshi IH, Riaz A, Khan RA, et al.Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice[J]. Metab Brain Dis, 2017, 32(4): 1051-1060.
[16] Chinese Journal of Pain Medicinc. Chinese expert consensus on diagnosis and treatment of post herpetic neuralgia [EB/OL].(2016-04-29)[2019-12-01]. http://yao.dxy.cn/article/490358.

带状疱疹神经痛患者应用普瑞巴林致肌阵挛的药学监护

Myoclonus Caused by Pregabalin in Patients with Herpes Zoster Neuralgia and Literature Analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.